cPass is first commercially available product to rapidly detect neutralizing antibodies capable of eliminating virus
AstraZeneca anticipates entering clinical development in 2021
The technology is said to be superior at identifying cell types in human blood, providing faster and more reliable assessments for clinical decision making
The new Elecsys Anti-SARS-CoV-2 S test can quantitatively measure the level of antibodies against SARS-CoV-2 in patients who have been exposed to the virus
The collaboration aims to define threshold for neutralizing antibody sufficient to confer immunity
New indication allows this first FDA-approved biomarker-based test to be used as triage for positive cobas HPV tests run on cobas 6800/8800 Systems in primary screening or co-testing programs
The agreement is part of preparations for GMP production of material for the first clinical study of CG01
New test expands Roche molecular test menu for transplant patients, enabling simultaneous testing of BK virus with Cytomegalovirus and Epstein-Barr virus
Sanofi and GSK are scaling up the manufacturing of the antigen and adjuvant with the target of producing up to one billion doses in 2021
Data shows 100% concordance with results from Dartmouth-Hitchcock’s lab-based polymerase chain reaction (PCR) test method
The new AI technology will learn from past CT scans of COVID-19 pneumonia patients, reducing the burden on doctors making diagnoses
Antigen test reliably and quickly triages people suspected of SARS-CoV-2, with results ready in 15 minutes, allowing informed treatment decisions
Avacta and Liverpool School of Tropical Medicine collaborate to clinically validate saliva-based rapid coronavirus test being developed with Cytiva
Test delivers results in just 15 minutes with no instrumentation, using proven lateral flow technology with demonstrated sensitivity of 97.1% and specificity of 98.5%
First participants dosed in trial of AZD7442 to assess safety, tolerability and pharmacokinetics of the combination
QIAseq SARS-CoV-2 Primer Panel converts viral RNA samples into libraries ready for sequencing, whereas QIAGEN Digital Insights solutions support COVID-19 drug, vaccine and epidemiology research
Syndromic testing will streamline respiratory infection diagnosis as COVID-19 pandemic collides with start of flu season
Across all populations, BNT162b2 administration was well tolerated with mild to moderate fever in fewer than 20% of the participants
Regeneron will distribute REGN-COV2 in the U.S. and Roche will be responsible for distribution outside the U.S.
It is the first and only approved therapy for NMOSD designed to target and inhibit interleukin-6 receptor activity, using novel recycling antibody technology
The consortium aims to determine the dynamics, function and potential for therapeutic intervention of the RNA and protein structures of SARS-CoV-2
IgM assay has 95.51% positive predictive value even when disease incidence is only 3%
Connecting the scientific community with two new online content-packed events
